

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

VOLUNTARY ANNOUNCEMENT IN RELATION TO CLASS ACTION LAWSUIT AGAINST SHAREHOLDERS

Reference is made to the prospectus of WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated May 31, 2017 (the “**Prospectus**”). Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the Prospectus.

The Company was informed that on February 21, 2019 (New York time), certain shareholders of the Company, including WuXi PharmaTech, five of its then directors and/or members of the senior management (including Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao) and other members of the buyer consortium involved in its Delisting (as defined below), were named as defendants (the “**Defendants**”) in a class action lawsuit filed in the United States District Court for the Southern District of New York (the “**Lawsuit**”). The Company was previously wholly owned by WuXi PharmaTech, whose shares were then listed on the NYSE, prior to the Reorganization. WuXi PharmaTech was taken private by the consortium and delisted from the NYSE on December 10, 2015 (the “**Delisting**”). WuXi PharmaTech and members of the consortium were alleged of material false statements and omissions in the relevant disclosure made in relation to the Delisting. The lead plaintiff was a former shareholder of WuXi PharmaTech before the Delisting and sought to, inter alia, recover damages caused by the Defendants and legal fees reasonably incurred in relation to the Lawsuit. No amount of damages was specified at this stage. Neither the Company nor any of its subsidiaries was named as a defendant in the Lawsuit.

The Company was also informed that the Defendants, after consulting their US legal advisors, are confident in putting forward a strong defence and will contest vigorously in the Lawsuit. The Company understands that such kind of class action lawsuits in relation to privatization of companies listed in the United States are not uncommon and are typically initiated by certain investors with the support of litigation firms specializing in shareholder class actions. Having considered, among others, that neither the Company nor any of its subsidiaries is a party to the Lawsuit, the Company is of the view that the Lawsuit does not have any material adverse impact on the operations and financial position of the Group as a whole.

Further announcements will be made in connection with the above matter as and when appropriate in accordance with the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

For and on behalf of
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, February 25, 2019

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

* *For identification purpose only*